Morepen Laboratories Ltd
Jatin Sahni has held various leadership positions in the pharmaceutical industry. Jatin served as Vice President at Morepen Laboratories Limited India from July 2017. Prior to this, they were the Managing Director at Molecules Lifesciences Private Limited starting from February 2013. Jatin also worked as the Director at Avron Chemicals Pvt Ltd from June 2010 to January 2012. Currently, they hold the position of Director at Gallen AG Private Limited since April 2022. In addition, they served as Head of Business Development at Life Diagnostics from February 2012 to March 2013.
Jatin Sahni completed a Bachelor of Business Administration (BBA) with a focus on Finance, General from Panjab University, Chandigarh in 2003. Jatin went on to earn a Master of Business Administration (MBA) in Pharmaceutical Marketing and Management from Ahmedabad University. Most recently, they completed a Global Executive MBA in Pharmaceutical Management from the University of California, San Diego - Rady School of Management in 2022, receiving a Statement of Completion.
This person is not in any offices
Morepen Laboratories Ltd
Morepen Laboratories Limited is a pharmaceutical company. The Company's divisions include Active Pharmaceutical Ingredients (API), Home Diagnostics and Finished Formulations. The API division offers products, such as Loratadine Process-1, Desloratadine, Atorvastatin Calcium Amorphous, Atorvastatin Calcium Crystalline Form VI and Linagliptin, among others. The Company offers products under the self-health diagnostic brand HomeHealth. Its HomeHealth portfolio includes automatic digital blood pressure monitors, digital and analog weighing scales, body and foot massagers, heat therapy range, nebulizers, pregnancy cards, and clinical and digital thermometers. The Company offers no coding blood glucose monitoring system under its brand, GlucoOne. It markets various brands of medical devices and clinical diagnostic products. The Company operates in India, the United States and Rest of World. Its subsidiaries include Dr. Morepen Limited, Total Care Limited and Morepen Inc.